Anixa Biosciences (ANIX) Financials

Anixa Biosciences (NASDAQ:ANIX) remains a pre-revenue biotechnology company with persistent operating losses and cash burn. The latest statements show some improvement in expense levels compared with 2024, but the company continues to rely on its investment portfolio and periodic equity financing to fund operations.

• Operating expenses have generally declined from 2024 levels. Quarterly operating expenses fell from $3.6 million in Q1 2024 to $2.7 million in Q3 2026. The improvement has been driven by lower selling, general and administrative costs, while research and development spending has remained comparatively stable.
• Liquidity remains substantial relative to liabilities. At July 31, 2026, Anixa reported $1.4 million of cash and $12.5 million of short-term investments, or approximately $13.9 million in highly liquid assets. Total liabilities were only $1.9 million, producing a current ratio of roughly 8.5 times.
• Quarterly losses have improved from earlier periods. Net loss attributable to common shareholders was $2.6 million in Q3 2026, compared with $3.2 million in Q1 2024 and $2.8 million in Q2 2025. Basic loss per share improved to $0.08 from $0.10 in early 2024.
• Investment income provides a modest offset to operating costs. Interest and investment income was $112,000 in Q3 2026 and has remained positive in every reported quarter in the supplied data, although it is not large enough to offset operating expenses.
• Anixa actively manages its short-term investment portfolio. The company has regularly purchased and sold or matured investments, generating relatively small net investing cash flows in most quarters. This activity appears to be portfolio management rather than operating growth, so it supports liquidity but does not represent recurring business revenue.
• Share count has gradually increased. Weighted average basic shares rose from approximately 31.0 million in Q3 2023 to 34.2 million in Q3 2026. The increase has been moderate, but additional equity issuance could dilute existing shareholders if losses continue.
• The company has reported zero revenue in every income statement provided. Anixa therefore has no demonstrated operating revenue stream to fund research, development or administrative expenses. Future financial performance remains dependent on potential product, partnership or licensing milestones that are not reflected in these statements.
• Operating cash flow remains consistently negative. Cash used in operations was $1.8 million in Q3 2026, following $1.7 million in Q2 and $2.6 million in Q1. Operating cash flow has been negative throughout the supplied history, indicating that the business is not yet self-funding.
• Cash and investments have declined materially over the longer term. Cash and short-term investments totaled approximately $13.9 million at July 31, 2026, down from $24.8 million at July 31, 2024 and $25.5 million at July 31, 2023. The decline reflects ongoing losses and cash usage despite investment sales and financing proceeds.
• External financing remains part of the funding model. Anixa received $1.9 million from common-equity issuance in Q3 2026 and reported financing inflows in several earlier quarters. Continued equity financing could extend the company’s runway, but it also creates dilution risk and underscores the lack of internally generated cash.

Overall, Anixa’s balance sheet is lightly leveraged and still provides a meaningful liquidity cushion, while lower operating expenses are an encouraging trend. However, the investment case remains highly dependent on the development and eventual commercialization of its biotechnology programs. Until revenue emerges, continued losses, negative operating cash flow and potential shareholder dilution remain the primary financial risks.